| Literature DB >> 17265423 |
Mahmoud Ghazi-Khansari1, Ali Mohammadi-Karakani, Masoud Sotoudeh, Parvin Mokhtary, Ebraheim Pour-Esmaeil, Shirin Maghsoud.
Abstract
Although different treatment modalities have been implemented for pulmonary fibrosis, the results have not been promising and these conditions have been considered untreatable and irreversible. Thus, a plethora of new drugs has been tried for the control of this condition in recent years. This study examined the effects of two angiotensin-converting enzyme inhibitors, captopril and enalapril, on paraquat-induced pulmonary fibrosis in rats, through biochemical and histopathological parameters. Male albino Wistar rats were divided into eight groups (n = 4-5 each), including control, paraquat, captopril alone, captopril treatment and pre-treatment, enalapril alone, enalapril treatment and pre-treatment. After 21 days of treatment, the lungs were removed and the levels of hydroxyproline, glutathione and lipid peroxidation were determined. Angiotensin-converting enzyme inhibitors showed no effect on glutathione and lipid peroxidation. The results also demonstrated that captopril and enalapril improved pulmonary fibrosis as shown by histopathology, as well as a decreased content of hydroxyproline (P < 0.001) in the lung tissue. In conclusion, the present findings suggest that the antifibrotic effect of these drugs may be related to the inhibition of angiotensin-converting enzyme. Copyright (c) 2007 John Wiley & Sons, Ltd.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17265423 DOI: 10.1002/jat.1212
Source DB: PubMed Journal: J Appl Toxicol ISSN: 0260-437X Impact factor: 3.446